Introduction {#sec1-1}
============

Hypertension is a major public health problem of modern era. Up to 28% of the world\'s adult population had uncontrolled hypertension in a study published in 2011.\[[@ref1]\] Anchala *et al.* reported an overall hypertension prevalence of 29.8% in India in their meta-analysis.\[[@ref2]\] The prevalence of hypertension in this study was significantly higher in urban Indians than in rural Indians (33.8% vs. 27.6%, respectively).\[[@ref2]\]

Hypertension if left untreated can lead to end organ damage, such as retinopathy, chronic kidney disease, cerebrovascular disease, heart failure, coronary artery disease, and atrial fibrillation. Various classes of drugs are available for treatment of hypertension. Among these angiotensin receptor blockers (ARBs) are most widely used antihypertensive drugs and have maximal patient acceptability profile. ARBs hold class I recommendation for pharmacological management of hypertension in various guidelines including European and American guidelines.\[[@ref3][@ref4][@ref5]\]

Mechanism of Action of ARBs {#sec1-2}
===========================

The ARBs selectively inhibit angiotensin II by competitive antagonism of the angiotensin receptors \[[Figure 1](#F1){ref-type="fig"}\]. Thereby, they antagonize angiotensin II-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, and water retention. These mechanisms reduce adverse effects and possibly improve clinical efficacy in comparison to angiotensin convertase enzyme inhibitors (ACEIs). The currently available ARBs are summarized briefly in [Table 1](#T1){ref-type="table"}.

![Mechanism of action of angiotensin convertase enzyme inhibitors and angiotensin receptor blockers](JFMPC-8-2184-g001){#F1}

###### 

Brief description of currently available ARBs ("Sartans")\[[@ref6][@ref7][@ref8][@ref9]\]

  Drug          Active Metabolite   Half Life (hours)            Starting Dose (mg)   Major Trials
  ------------- ------------------- ---------------------------- -------------------- ----------------------------
  Candesartan   Yes                 3.5-4 (3-11 of metabolite)   16                   SCOPE, DIRECT-PREVENT
  Eprosartan    No                  5-7                          600                  MOSES, OSCAR
  Irbesartan    No                  11-15                        150                  IRMA-2, IDNT
  Losartan      Yes                 2 (6-9 of metabolite)        50                   RENAAL, LIFE
  Olmesartan    Yes                 13                           20                   ORIENT, ROADMAP,
  Telmisartan   No                  24                           40                   PROFESS, TRANSCEND
  Azilsartan    No                  11                           50                   Bakris et al., Sica et al.
  Valsartan     No                  9                            80                   NAVIGATOR
  Fimasartan    No                  5-16                         30                   Safe-KanArb

Fimasartan - the Latest "sartan" {#sec1-3}
================================

Fimasartan is a latest\[[@ref9]\] angiotensin II receptor antagonist with selectivity for the AT(1) receptor subtype, developed by a korean company Boryung Pharmaceutical as an oral antihypertensive drug. [Figure 2](#F2){ref-type="fig"} demonstrates journey of ARBs from first marketed ARB molecule to recently introduced fimasartan. Fimasartan has been approved for use in patients with hypertension by FDA of Korea. Boryung has also got approval for this molecule in many other countries such as China, Singapore, and Russia. Fimasartan has also been approved in India by CDSCO (Central Drugs Standard Control Organization) recently.

![Development journey of angiotensin receptor blockers](JFMPC-8-2184-g002){#F2}

Fimasartan is a biochemical derivative of losartan in which the imidazole ring has been replaced. This change provides higher potency and longer duration of action to this molecule. Fimasartan is selective angiotensin II type 1 (AT~1~) receptor antagonist.\[[@ref10]\] In contrast to other ARBs, it did not show agonistic action to AT~2~ receptor in animal models.\[[@ref11]\]

Pharmacokinetics and Dynamics {#sec1-4}
=============================

The pharmacokinetics and pharmacodynamics of fimasartan are highlighted in [Table 2](#T2){ref-type="table"}. It is a long acting drug, requiring once daily dosing. It is usually given in dosage of 60--120 mg OD. The onset of action of fimasartan is faster that it\'s congeners. It is usually well tolerated in mild to moderate renal dysfunction, but dose reduction is required in severe renal dysfunction (\<30 mL/min creatinine clearance starting dose is 30 mg OD). It is safe in mild hepatic dysfunction. Fimasartan should be avoided in severe hepatic dysfunction, patients on hemodialysis, pregnant or nursing mothers, and patients with hypersensitivity reaction.

###### 

Pharmacokinetics and pharmacodynamics of fimasartan\[[@ref9][@ref10][@ref11]\]

  Half life                    5-16 h
  ---------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  Protein binding              95%
  Bioavailability              18.6%
  Metabolism                   \>90% stable
  Excretion                    Predominantly fecal and biliary, only 2% renal
  Dosage                       60-120 mg OD orally with or without food
  Renal impairment             No dose adjustment required in mild to moderate renal impairment, but \<30 mL/min creatinine clearance starting dose is 30 mg OD
  Hepatic impairment           The drug is not recommended in moderate to severe hepatic impairment
  In pregnancy and lactation   Not recommended
  Adverse reactions            Headache, dizziness Syncope, dyspepsia, asthenia,
  Common                       Muscular twitching, pruritus, cough, erectile dysfunction
  Uncommon                     

The drug has been well tolerated in clinical studies. Most adverse reactions were transient and not dose related. Headache and dizziness were the most common ones reported. Other reported side effects include nausea, pain abdomen, cough, pruritus, hot flushes, increased liver enzymes, etc.

Clinical Evidence for Use in Hypertension {#sec1-5}
=========================================

We have now accumulated data for fimasartan use in close to 20,000 patients. Fimasartan was found to have an excellent efficacy and tolerability profile in a large-scale observational population study - Safe-KanArb. In this study, a total of 14,151 patients with mean age of 59 ± 12 years were evaluated. This study established the safety, efficacy, and compliance of this molecule. The Systolic blood pressure (SBP) fell by an average of -18.65 mm of Hg and Diastolic blood pressure by - 9.73 mm of Hg with drug therapy at 2 months. Interestingly, the pulse rate declined from 74.4 to 71.9 beats per min in the treatment arm. The benefits were attained irrespective of age, sex, comorbidities and background antihypertensive therapy. It should be noted that more than half of the study population (63%) was on background anti-hypertensive therapy underscoring the potency and efficacy of the drug. The drug was found to be excellent in patients potentially at higher risk for adverse events.\[[@ref12]\]

The K-MetS study of 10601 patients was planned to evaluate long-term effects of fimasartan on major adverse cardiovascular outcomes. The study also evaluated long-term metabolic effects of fimasartan. Three-year follow-up was planned in this study. At 1-year follow-up, in a sub group analysis published in 2017, fimasaratn significantly decreased the albumin/creatinine ratio. The systolic blood pressure fell from 143.7 ± 17.2 mm of Hg to 126.7 ± 12.6 mm of Hg at 1 year (a fall of around 17 mm of Hg). On a similar note, the diastolic BP decreased from 88.4 ± 11.48 at baseline to 78.6 ± 8 mm of Hg. Waist circumference and triglyceride levels were also diminished simultaneously.\[[@ref13]\]

In another study, the drug was associated with reduction in day to day BP variability independent of absolute BP reduction.\[[@ref14]\] Fimasartan was similarly effective in reducing Systolic as well as diastolic BP in hypertensive elderly patients compared with nonelderly patients in a sub group analysis of K-MetS study. It also resulted in better pulse pressure reduction with similar home blood pressure reduction efficacy and safety in hypertensive elderly patients.\[[@ref22]\]

One recent study evaluated the effects of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation using 18F-fluorodeoxyglucose positron emission tomography imaging. Both drugs were found to decrease carotid atherosclerotic plaque inflammation similarly in patients with acute coronary syndrome.\[[@ref23]\] The major studies done with fimasartan so far are depicted in [Table 3](#T3){ref-type="table"}.

###### 

Major studies establishing the clinical role of fimasartan in hypertension.\[[@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21]\]\[BP-Blood Pressure; FMS- Fimasartan; HCTZ-Hydrochlorthiazide\]

  Study                           Number of Patients   Study Drugs                                             Key Findings
  ------------------------------- -------------------- ------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------
  Cardona et al.\[[@ref15]\]      272                  60 and 120 mg FMS alone or combined with HCTZ           FMS safe and effective in grade 1-2 essential hypertension
  Shin et al.\[[@ref14]\]         1,396                30-120 mg FMS for 3 months                              3 months of FMS reduces day-to-day BP variability independent of BP reduction
  Safe-KanArb Study\[[@ref12]\]   14,151               60 or 120 mg OD                                         Established efficacy, safety, and tolerability of FMS
  K-Mets study\[[@ref13]\]        3,250                FMS for 3 months                                        FMS reduced the albumin/creatinine ratio in hypertensive patients
  Duran et al.\[[@ref16]\]        40                   60-120 mg FMS                                           FMS reduced SBP, DBP adequately with decrease in albuminuria at 24 weeks
  Lee et al.\[[@ref17]\]          75                   Low-dose FMS (30 mg) or valsartan 80 mg daily           Low dose FMS lowers 24 hrs BP comparable to valsartan in mild to moderate hypertension
  Lee et al.\[[@ref18]\]          92                   FMS 60-120 mg or valsartan 80 mg daily for 8 weeks      Once daily FMS effectively maintained BP maintained over 24 h dosing interval comparable to slightly better than valsartan
  Rhee et al.\[[@ref19]\]         263                  60-120 mg once daily FMS alone or with 12.5 mg HCTZ     Combination therapy achieved better BP control than FMS monotherapy and had comparable safety and tolerance to FMS monotherapy
  Kim et al.\[[@ref20]\]          143                  FMS 60 mg monotherapy or FMS 60 mg + amlodipine 10 mg   Combination therapy produced superior BP reductions and low levels of adverse effects compared with monotherapy.
  Yang et al.\[[@ref21]\]         41                   FMS 60-120 mg or amlodipine 5-10 mg for 16 weeks        Compared with amlodipine FMS increased late phase insulin release in patients with type 2 diabetes mellitus and hypertension

Implications for Clinical Practice {#sec1-6}
==================================

The prevalence of hypertension is continuously rising, yet the proportion of patient\'s with their blood pressures under target remains low. The ACC/AHA 2017 hypertension guidelines suggest that most of the hypertensive patients will need combination therapy for attaining BP goals. In real world, primary care physician (not the cardiologist) is usually the first contact of a patient for hypertension consultation. So longer acting, potent antihypertensive drugs with least side effect profile are needed to make the task of hypertension control easy. ARBs have proven their efficacy in treatment of hypertension for past two decades. They have most favorable side effect profile among current antihypertensive portfolio. Fimasartan is newer longer acting and potent ARB. So, it can be safely used by primary care physician in an efficient manner for management of hypertension.

Future Directions {#sec1-7}
=================

FANTASTIC study will assess renoprotective effect of fimasartan and the target blood pressure to reduce adverse outcomes in hypertensive diabetic chronic kidney disease patients with overt proteinuria.\[[@ref24]\] The safety and efficacy of drug in elderly patients (\>70 years) against perindopril is being evaluated in FITNESS study (NCT 03246555). The FRESH (FimasaRtan-basEd BP Targets After Drug SwitcHing) study aimed to find proportion of patients achieving BP goals after switching to fimasartan-based regimens in patients with uncontrolled hypertension (NCT 03649646).

Conclusion {#sec1-8}
==========

A good number of clinical evidences support the use of this newer, potent, longer acting ARB- Fimasartan \[See [Figure 3](#F3){ref-type="fig"}\]. Fimasartan achieved clinically significant blood pressure reduction in various studies with effect persisting over 24 h dosing interval. It was also shown to be renoprotective too. Apart from being efficacious, it has also demonstrated safety in elderly and high risk populations. So, this newer ARB has shown promising results in terms of efficacy, safety, and tolerability in clinical studies. The molecule is currently being used in number of countries in treatment of hypertension. In India, it has been launched recently. Fimasartan appears as a promising drug for management of hypertension for future in our country.
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